GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Disc Medicine Inc (NAS:IRON) » Definitions » EPS without NRI

IRON (Disc Medicine) EPS without NRI : $-3.98 (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Disc Medicine EPS without NRI?

Disc Medicine's earnings per share without non-recurring items for the three months ended in Sep. 2024 was $-0.89. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.98.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 27.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Disc Medicine's EPS without NRI or its related term are showing as below:

IRON' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 27.6   Med: 27.6   Max: 27.6
Current: 27.6

During the past 4 years, Disc Medicine's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 27.60% per year. The lowest was 27.60% per year. And the median was 27.60% per year.

IRON's 3-Year EPS without NRI Growth Rate is ranked better than
77% of 1239 companies
in the Biotechnology industry
Industry Median: 4.6 vs IRON: 27.60

Disc Medicine's EPS (Diluted) for the three months ended in Sep. 2024 was $-0.89. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.98.

Disc Medicine's EPS (Basic) for the three months ended in Sep. 2024 was $-0.89. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.98.


Disc Medicine EPS without NRI Historical Data

The historical data trend for Disc Medicine's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Disc Medicine EPS without NRI Chart

Disc Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EPS without NRI
-9.01 -35.20 -44.99 -3.42

Disc Medicine Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.58 -0.97 -1.09 -1.03 -0.89

Competitive Comparison of Disc Medicine's EPS without NRI

For the Biotechnology subindustry, Disc Medicine's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Disc Medicine's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Disc Medicine's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Disc Medicine's PE Ratio without NRI falls into.



Disc Medicine EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Disc Medicine  (NAS:IRON) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Disc Medicine EPS without NRI Related Terms

Thank you for viewing the detailed overview of Disc Medicine's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Disc Medicine Business Description

Traded in Other Exchanges
N/A
Address
321 Arsenal Street, Suite 101, Watertown, MA, USA, 02472
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.
Executives
William Richard White director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
William Jacob Savage officer: Chief Medical Officer C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Kevin Bitterman director C/O POLARIS VENTURE PARTNERS, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02451
Mona Ashiya director, 10 percent owner C/O SIERRA ONCOLOGY, INC., 2150 - 885 WEST GEORGIA STREET, VANCOUVER, BRITISH COLUMBIA Z4 V6C 3E8
Atlas Venture Fund X, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Joanne Bryce officer: Chief Financial Officer C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Rahul Khara officer: General Counsel C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Brian Richard Macdonald officer: Chief Innovation Officer C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Ai Dmi Llc 10 percent owner C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Atlas Venture Associates Opportunity I, Llc 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity I, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates X, Llc 10 percent owner 400 TECH. SQ., 10TH FLOOR, CAMBRIDGE MA 02139
Access Industries Holdings Llc 10 percent owner C/O ACCESS INDUSTRIES MANAGEMENT, LLC., 730 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10019